MedTrace Logo

Clinical Study to CMDHA0101 as Compared to PowerFill® for Temporary Penile Enhancement

NCT03153735 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2017-12-12

No results posted yet for this study

Summary

The investigators aimed to confirm the efficacy and safety of transdermal penis enlargement for 24 weeks after CMDHA0101 injection in subjects who wanted penile enlargement in male patients with small-penis syndrome \*.

\*Small-penis syndrome is the anxiety of thinking one's penis is too small - even though it isn't.

Conditions

  • Small Penis
  • Penile Enhancement

Interventions

DEVICE

CMDHA0101

Maximum injection dose : 22 ml

DEVICE

PowerFill®

Maximum injection dose : 22 ml

Sponsors & Collaborators

  • CHA MEDITECH Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Dae Yul Yang, Director · Hallym University Kangdong Sacred Heart Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-12-02
Primary Completion
2017-11-07
Completion
2017-11-07

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03153735 on ClinicalTrials.gov